The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB(2024) IUIS 2023: yEFIS workshop on career development and code-switching Eur J Immunol, e2451155(in press) DOI 10.1002/eji.202451155, PubMed 38676471
Fleischer T, Haugen MH, Ankill J, Silwal-Pandit L, Børresen-Dale AL, Hedenfalk I, Hatschek T, Tost J, Engebraaten O, Kristensen VN(2024) An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer Mol Oncol(in press) DOI 10.1002/1878-0261.13656, PubMed 38671580
Martin KE, Hammer Q, Perica K, Sadelain M, Malmberg KJ(2024) Engineering immune-evasive allogeneic cellular immunotherapies Nat Rev Immunol(in press) DOI 10.1038/s41577-024-01022-8, PubMed 38658708
Esperon P, Neffa F, Pavicic W, Spirandelli F, Alvarez K, Mullins MJ, Rossi BM, Góngora E Silva RF, Vaccaro C, Lopéz-Köstner F, Rugeles J, Valle AD, Dominguez-Valentin M(2024) A comprehensive characterization of the spectrum of MUTYH germline pathogenic variants in Latin America Fam Cancer(in press) DOI 10.1007/s10689-024-00382-3, PubMed 38687439
Kempkes RWM, Nikolaou C, Nabhan M, Saidu NEB(2024) IUIS 2023: yEFIS workshop on career development and code-switching Eur J Immunol, e2451155(in press) DOI 10.1002/eji.202451155, PubMed 38676471
Dodd DO, Mechaussier S, Yeyati PL, McPhie F, Anderson JR, Khoo CJ, Shoemark A, Gupta DK, Attard T, Zariwala MA, Legendre M, Bracht D, Wallmeier J, Gui M, Fassad MR, Parry DA, Tennant PA, Meynert A, Wheway G, Fares-Taie L, Black HA, Mitri-Frangieh R, Faucon C, Kaplan J, Patel Met al.(2024) Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules Science, 384(6694), eadf5489 DOI 10.1126/science.adf5489, PubMed 38662826